Becton, Dickinson and Company (BDX) Q4 2014 Earnings Report, Transcript and Summary

Monique Dolecki - Vincent A. Forlenza - Chairman, Chief Executive Officer and President Christopher R. Reidy - Chief Financial Officer and Executive Vice President of Administration Tom Polen - President Linda M. Tharby - Segment President of Life Sciences Alberto Mas -

Michael N. Weinstein - JP Morgan Chase & Co, Research Division David H. Roman - Goldman Sachs Group Inc., Research Division Frederick A. Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Scott Alan Lange Kristen M. Stewart - Deutsche Bank AG, Research Division William R. Quirk - Piper Jaffray Companies, Research Division Douglas Schenkel - Cowen and Company, LLC, Research Division S. Brandon Couillard - Jefferies LLC, Research Division Brian Weinstein - William Blair & Company L.L.C., Research Division Vijay Kumar - ISI Group Inc., Research Division Glenn J. Novarro - RBC Capital Markets, LLC, Research Division Ravi Misra - Leerink Swann LLC, Research Division Derik De Bruin - BofA Merrill Lynch, Research Division Mark Massaro - Canaccord Genuity, Research Division

Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2014 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 11, 2014, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and (404) 537-3406 for international calls, using confirmation number 14009656. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin.

Thank you, Christie. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com. During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our fourth fiscal quarter press release and in the MD&A sections of our recent SEC filings. We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website. Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Chief Financial Officer and Executive Vice President of Administration; Bill Kozy, Executive Vice President and Chief Operating Officer; Tom Polen, Segment President; Linda Tharby, Segment President; and Alberto Mas, President of Diagnostic Systems. At this time, we would like to announce some leadership changes, which took place on October 1. Beginning in fiscal year 2015, we will organize BD into a 2-segment structure, which consists of a Medical and Life Sciences segment. Tom Polen has been promoted to the role of Segment President for BD Medical. This segment is comprised of the Medical Surgical Systems, Pharmaceutical Systems and Diabetes Care business units. Linda Tharby has been promoted to the role of Segment President for our Life Sciences segment. This segment is comprised of the Preanalytical Systems, Diagnostic Systems and Biosciences business units. In their new roles, Linda and Tom will continue to report to Bill Kozy, Executive Vice President and Chief Operating Officer. For the purposes of today's call, Tom will answer any questions related to Medical, and Linda will answer any questions related to Life Sciences. As we stated in our press release, earnings per share were impacted by some onetime charges this quarter. Further information about these charges and other adjustments in the current and prior year can be found in the additional reconciliation of non-GAAP financial measures. For the purposes of our conference call today, we will refer to adjusted diluted earnings per share excluding these charges. The medical device tax in the first quarter of this fiscal year 2014 was $14 million or $0.05 per share. In certain circumstances, we will also exclude the medical device tax from our results. Please note that all fiscal year 2015 guidance provided is on a BD standalone basis. As we move closer to our anticipated closing of the CareFusion acquisition, we will provide more explicit guidance on the pro forma financials for the combined company. We would also like to remind everyone that going forward, adjusted EPS will also exclude the amortization of acquisition-related intangibles. When we refer to EPS in our remarks, unless otherwise noted, we are referring to adjusted cash EPS. Also, guidance will be provided for Diagnostics and Biosciences for fiscal year 2015. However, beyond 2015, our guidance will reflect our new structure. It is now my pleasure to turn the call over to Vince.

Thank you, Monique, and good morning, everyone. Before we discuss the company's performance, I would like to comment briefly on the organizational changes Monique just walked you through. Last November, we had announced the promotions of Linda and Tom to Group President, as well as several other leadership changes. Over the past year, we have continued to bolster our leadership structure to help ensure our future success and continued development of our senior leaders. This new structure is more reflective of the company's strategy and increased focus on growth as we develop more impactful solutions for our customers. The change to a 2-segment structure will also enable us to seek strategic synergies across our portfolio, with the CareFusion business being reported within our Medical segment once the transaction is completed. We are extremely pleased to have Tom and Linda in their new roles as they help lead the company through our next phase of growth. Turning to Slide 4, I would like to highlight some key achievements in fiscal year 2014. First, our strategy of investing and innovating for growth continues to deliver results as evidenced by our strong finish to the year. Revenue growth was a -- was robust at 5.2%, which includes 20 basis points of growth from acquisitions. Our core remains strong, and our product pipeline continues to drive growth across the portfolio with new products as a percentage of revenue going from 13% to about 15% over the past year. Second, we have continued to strategically invest in higher-growth emerging markets. We made an incremental investment of $40 million in fiscal year 2014. Emerging markets grew over 12% and continued to be a key driver of growth for the company. We have one of the highest percentages of sales in emerging markets in our peer group at about 25% of total revenue. And third, we have continued to refine our operating effectiveness and efficiency initiatives, which continue to drive underlying margin expansion. Our ReLoCo program has benefited us incrementally by more than $30 million this year. We remain focused on these programs and also on efficient utilization of our global shared service centers and end-to-end process improvement opportunities. Fourth, we completed our 42nd consecutive year of dividend increases and also repurchased $400 million in shares through our share repurchase program, which highlights our effective deployment of capital. Finally, we have built a strong foundation for continued growth. We continue to proactively adapt to today's dynamic health care environment by transitioning from a product-focused company to a customer-focused provider of health care solutions. Our announced acquisition of CareFusion helps us significantly accelerate that strategy. The powerful combination of the 2 companies will further enable us to deliver end-to-end solutions that increase efficiencies, reduce medication errors and improve patient safety in both hospitals and pharmacies. Moving to Slide 5, you will see the guidance for fiscal year 2015 on a currency-neutral basis. For fiscal year 2015, we expect currency-neutral revenue growth of 4.5% to 5% based on our current view of the environment. Of course, we have contemplated a number of factors that could bring us above or below that range including pricing, a stronger or weaker flu season than expected, product launches, emerging market growth, macroeconomic conditions and the impact of the Affordable Care Act. On the bottom line, we will continue to drive high-quality earnings growth. For fiscal year 2015, we expect adjusted EPS growth to be between 8% and 9%. When excluding the unfavorable impact of the suspension of our share repurchase program, EPS growth would be between 9% and 10%. Now I'd like to turn the call over to Chris, who will walk you through our financial performance in the fourth quarter, along with additional details about our fiscal year 2015 guidance.

Thanks, Vince, and good morning, everyone. I'd like to begin on Slide 7 by discussing the key highlights for the fourth quarter, which I'll speak to on a currency-neutral basis. We are pleased with our fourth quarter results. Solid revenue growth of 4.6% was driven by our Medical and Diagnostics segment. As we anticipated and communicated on our last call, pricing declined about 50 basis points in the quarter, bringing the total year pricing impact to about flat. Biosciences growth was impacted by an unfavorable comparison to the prior year, as we expected. We continue to see strong growth in emerging markets and international safety sales. We also experienced a tax rate benefit in the quarter, which was offset by unfavorable currency. This quarter, we recorded EPS pretax charges totaling $46 million or $0.15 per share, which primarily consisted of a workforce reduction charge as a result of operational restructuring activities. Adjusted EPS growth in the quarter was strong at 13%. On Slide 8, I'll review our revenue growth by segment on a currency-neutral basis. Fourth quarter revenue growth was 4.6% for the total company. BD Medical fourth quarter revenues increased 6.1%. Growth in this segment was driven by good performance in all 3 business units. Medical Surgical Systems' growth was 4.7%, with continued strength in emerging markets and international safety sales. Growth in Diabetes Care was 8.1%. This reflects the continued strength of pen needle sales and a favorable comparison to the prior year. Pharmaceutical Systems' growth of 7% was favorably impacted by ordering patterns. For the total year, the Medical segment grew 6.3%, which was aided by a nonannualized acquisition. This contributed about 30 basis points, bringing organic growth to 6.0%. BD Diagnostics' fourth quarter revenues increased 4.2%. The segment's growth was driven by solid sales of Preanalytical Systems' safety-engineered products and solid growth in Diagnostic Systems. Diagnostic Systems benefited from strong sales in microbiology and continued progress with our KIESTRA rollout. For the total year, the Diagnostics segment grew 3.3%. BD Biosciences' revenue growth was about flat in the quarter, which was impacted by an unfavorable comparison to the prior year. You may recall last year, we had a particularly strong fourth quarter related to timing in Western Europe and Japan's stimulus revenues. For the total year, the Biosciences segment grew 5.5%. Moving to Slide 9, I'll walk you through our geographic revenues for the fourth quarter on a currency-neutral basis. BD's reported U.S. revenues increased 2.3% versus the prior year. We continue to view the hospital environment in the U.S. as stable. Revenue in our U.S. Medical segment increased by 3.4%. Strong growth in Diabetes Care was driven by pen needle revenues, which include our BD Nano and BD AutoShield Duo product. Growth was also aided, in part, by a favorable prior year comparison, as previously mentioned. U.S. Diagnostics' results were flat for the quarter. This reflects solid growth in Preanalytical Systems and strong growth in microbiology. This was offset by continued softness in Women's Health and Cancer due to extended cervical cancer screening intervals. We also continued to experience U.S. share losses in our ProbeTec business, which is consistent with what we've communicated the past 2 quarters. U.S. Biosciences' revenues grew 4.4%, driven by solid reagent and instrument growth. Moving on to international. We continue to see strong growth. Revenues grew 6.2%, driven by solid growth in Medical and Diagnostics, both of which grew 7.8%. Both segments experienced strong growth in emerging markets and international safety sales. Biosciences declined 1.8%. This was due to the aforementioned prior year comparison, primarily due to timing in Western Europe. For the total year, U.S. revenues grew 1.9%, and international revenues grew 7.6%. On Slide 10, emerging market revenues grew 13.2%, currency-neutral, and accounted for over 26% of our total revenues. This strong performance was driven by growth in Medical and Diagnostics. China revenues grew by 21.4%, and safety sales in emerging markets grew by 18.6%. We saw a double-digit growth across all emerging markets in the fourth quarter and for the total year. As we continue to build our infrastructure and focus on localized R&D, it is evident that our investments in emerging markets continue to drive robust growth for the company. Moving to global safety on Slide 11. Currency-neutral sales increased 5.5% and grew to $566 million in the quarter. Revenues in the U.S. declined about 0.8%, which was impacted by an unfavorable comparison to the prior year. International safety sales grew 13.7%. Medical safety sales grew 6.4%, while Diagnostics grew 4.6%, driven by a range of safety-engineered products. For the total year, safety revenue grew 6.6%, currency-neutral, driven by strong international growth of 12.3%. Turning to Slide 12. Foreign currency had an unfavorable impact of about 80 basis points on our gross profit margin in the quarter, which was higher than our expectations. On a performance basis, margin expansion was driven by positive contributions from ReLoCo, continuous improvement and pension. These contributions were more than offset by the unfavorable impact of mix, pricing, start-up-related costs and raw materials. Slide 13 recaps the fourth quarter income statement and highlights our foreign currency-neutral results. Since we've already discussed revenue and gross profit, I'll move down the income statement to SSG&A. As a percentage of sales, SSG&A decreased in the quarter. This was driven by sustained cost containment, a favorable comparison to the prior period's legal expenses and favorable pension benefit. R&D was 6.0% of sales in the quarter, which was in line with our expectations as we continue to invest in new products and platforms. Operating income grew 10.1%, driven by solid revenue and gross profit growth, coupled with better leverage in SSG&A. Our tax rate improved 280 basis points over the prior year, which was largely contemplated in our guidance. The improvement was due to favorable geographic mix. Adjusted EPS in the quarter was $1.68 or an increase of 13%. Turning to Slide 14, I'd like to walk you through our expected revenue guidance for the full fiscal year 2015. In summary, we expect revenue growth of 4.5% to 5% on a currency-neutral basis. From a timing perspective, we expect currency-neutral revenue growth in the first quarter to be below the low end of this range due to an unfavorable comparison to the prior year period. On a reported basis, revenue growth is expected to be between 2% and 2.5%, reflecting an FX headwind of 200 to 250 basis points. This assumes a euro-to-dollar exchange ratio of $1.27. At current spot rates, all major currencies relative to the U.S. dollar are down about 8% versus the first quarter of 2014. We expect this unfavorable impact to be most acute in the first quarter with a headwind greater than 250 basis points. We expect the currency impact to moderate through the rest of the year. Moving on to the segments. We expect BD Medical to grow between 4.5% to 5%. This is a slightly lower growth profile than we experienced in fiscal year 2014 due to share gains and a benefit from the SSI acquisition. We expect our Life Sciences segment to grow about 4.5%. And within Life Sciences, we expect Diagnostics to grow between 4% to 4.5% and Biosciences to grow about 4.5% to 5%. Our acquisitions have annualized and will be included in our base going forward. This excludes our 2 most recently closed acquisitions, which are not expected to contribute materially to revenue in fiscal year 2015. We expect revenue growth to continue to be driven by new product launches in all 3 of our segments, continued growth of safety-engineered devices and emerging markets. We anticipate emerging market growth in fiscal year 2015 to be broadly in line with 2014 growth. The growth drivers I just mentioned will be partially offset by the expected unfavorable impact of pricing pressure. Based on our current view of the environment, we expect pricing to normalize at about 30 to 40 basis points of pressure for the year. Now moving on to Slide 15. There are a number of moving parts that impact earnings per share in fiscal year 2015. For modeling purposes and to ensure consistency, I'd like to provide more color on EPS guidance. When we announced the CareFusion acquisition, we informed you that we would be moving to an adjusted cash EPS basis to increase transparency into our underlying business performance. Going forward, that means that we will add back the amortization of acquisition-related intangibles to adjusted earnings per share. For fiscal year 2014, this changed our adjusted EPS from $6.25 to $6.50, which is ratable across all 4 quarters. For fiscal year 2015, we expect to grow earnings by about 9% to 10% on an underlying basis. This is very consistent with the earnings growth profile we have communicated for some time. The unfavorable impact of the suspension of our share repurchase program is worth about 100 basis points, bringing earnings growth to 8% to 9%. Assuming current spot rates, the unfavorable impact of foreign currency is about 400 basis points, bringing adjusted earnings growth to 4% to 5%. From a timing perspective, the impact of unfavorable currency will be most acute in the first quarter, similar to revenue. In the first quarter, we expect EPS to be about flat when compared with the first quarter of fiscal year 2014. For the first half of the year, we expect currency-neutral earnings growth to track slightly below our guided range of 8% to 9%. Turning to Slide 16. I'd like to walk through our additional elements of our guidance for the full fiscal year 2015. As a reminder, all fiscal year 2015 guidance will exclude the amortization of acquisition-related intangibles. We expect gross profit margin to be approximately 52%. Performance improvements are largely offset by negative currency translation, pricing pressure and pension. Our ReLoCo cost savings program is expected to deliver savings broadly in line with benefits experienced in fiscal year 2014. SSG&A as a percentage of sales is expected to be about 25%. Our guidance also reflects continued investments in emerging markets, as well as costs related to new product launches. We expect our R&D investment to be in line with fiscal year 2014 at about 6% of revenues. We continue to invest in new products and platforms, including incremental R&D investments in emerging markets. As a result of the items I just detailed, operating margin is expected to be between 20.5% and 21% of revenues. Excluding the unfavorable impact of foreign currency, we expect our underlying operating margin to improve by about 40 to 50 basis points. This also excludes pension headwinds, which equal approximately half of the margin expansion. We expect our tax rate to be between 21.5% and 22.5% as we continue to see improvement from geographic mix. For fiscal year 2015, we anticipate our average fully diluted share count to be broadly in line with fiscal year 2014. Cash flow is expected to remain strong with operating cash flow of about $1.85 billion in fiscal year 2015. Capital expenditures are expected to be about $625 million. Our guidance also contemplates the GenCell acquisition, which does not materially impact earnings. With respect to our anticipated CareFusion acquisition, things are progressing according to plan, and we do not have any updates to the financial parameters we've described when we announced the deal last month. Now I'd like to turn the call back over to Vince, who will provide you with an update on our product portfolio.

Thank you, Chris. Thank you, Chris. Before I review our pipeline, I would like to take a moment to provide a quick integration update on the CareFusion acquisition and make a few remarks about our recent acquisition of GenCell. While we announced the -- we just announced the CareFusion acquisition 1 month ago, our planning efforts are in line with where we expected to be and are off to a great start. I've had the opportunity to visit CareFusion's headquarters and have met with a number of the CareFusion associates. As we spend more time together, I feel even more confident that the complementary nature of our 2 companies will make for a successful integration. As we shared with you on our investor conference call on October 6, Bill Kozy is leading this integration effort. Our integration team is in place, which includes key members from BD and CareFusion. There has been a great deal of planning, hard work and activity in a short period of time. In a sizable acquisition like this, the success of the integration is of critical importance, and we will continue to keep you updated as we move forward. We are also underway with the integration activities of our latest acquisition in the Life Science area with our acquisition of GenCell. GenCell is a small biotech company that has developed proprietary technology to address key biological analysis protocols for library preparation for Next Generation Sequencing and genotyping applications. These technologies automate library preparation workflow, making it more efficient, reliable and less costly to perform. Next Generation Sequencing is a fast-growing space that represents a great opportunity for BD. As the NGS market moves to the clinic, BD is well positioned with relevant experience in bringing products from research to clinical markets, preanalytical sample collection and sample preparation in Diagnostic Systems. BD will combine this experience with GenCell's proprietary technology to meet unmet needs with upfront NGS workflow. Moving on to Slide 18. We have been discussing our robust pipeline for some time now. And in fiscal year 2014, there were a number of product launches. I will not review them in detail, but they are highlighted on Slides 18 and 19. We are committed to the successful ramp-up of these products, while we also look to the future and continue to expand our portfolio. Moving on to Slide 20. We have some new product launches that we would like to share with you. We are very excited about a new product in the insulin infusion set category, which we -- which you have heard us talk about for some time now. This new product introduction is the result of the work we have been doing together with the Juveniles -- Juvenile Diabetes Research Foundation. The BD infusion set is aimed at improving the consistency of insulin delivery for the users of durable infusion pumps, which aligns with the clinical goal of tight glycemic control and avoiding hyperglycemic episodes. We expect FDA clearance for this product in the second half of fiscal year 2015. We will update you on the product launch timing as we continue to make progress. For BD Simplist, we recently received FDA approval of midazolam. As we shared with you recently, BD Simplist requires a change in clinical processes, and uptake has been slower than expected. Those who have converted are pleased with the product. We have taken actions to reprioritize our portfolio to focus on drugs where a ready-to-use prefilled syringe is most valued by our customers, specifically those with the highest risk of medication errors or those used in the urgent care setting. The next 2 drugs meeting those criteria are hydromorphone and heparin, both expected to launch in 2016. We will continue to keep you updated as our launches progress. In Biosciences, we recently launched in Europe the first component of our BD OneFlow Solution for clinical reagents. This reagent and standardized instrument solution provides powerful analysis capabilities to improve efficiency, accuracy and objectivity in leukemia and lymphoma diagnosis. We also recently launched 3 new BD Horizon dyes and will be anticipating launching several more dyes in 2015. Our novel BD Horizon dyes, based on Sirigen technology, are used by external researchers to perform complex multi-color analysis and have increased the number of parameters or colors by which single cells can be analyzed using flow cytometry. In fiscal year 2015, we expect to launch the X-14 research instrument to deliver high-performance multi-color analysis with a compact footprint and a unique optical configurations to enable use of traditional or the novel BD Horizon Brilliant reagent portfolio for a wide variety of research applications. We are also looking forward to the launch of our BD FACSVia instrument. The FACSVia is based on the Accuri platform and is a low-cost, easy-to-use instrument for clinical applications. We're targeting this launch primarily for emerging markets, with an initial focus on China. On Slide 21, you can see the anticipated products in our Diagnostics business. On the BD MAX, we will be building upon the solid base of our novel assay launches in 2014, such as MRSA XT and our Enteric Panels. Our enteric strategy for 2015 includes assays for parasites as well as extended bacterial and viral testing. The availability of rapid molecular tests in these areas represents a significant improvement to the current testing methods available today, and we are confident that this will bring meaningful benefits to our customers. Our GC/CT assay is expected to launch in Europe in the third quarter of this year. This is a test that we currently have on our BD Viper instrument, which will now be available for our BD MAX customers as well. We are expecting the full launch of the BD Totalys system in our Women's Health and Cancer area. This front-end automation system for screening cervical cancer has already been well received in Europe this year, and we look forward to its launch in the U.S. As you can see, we continue to have strong opportunities in our pipeline, and we look forward to sharing our progress with you as we make progress throughout the year. Before I summarize the presentation and open up this call for questions, I'd like to take a moment to address the Ebola epidemic. We have been working with a number of foundations to provide essential medical supplies and support and have donated about $850,000 to date in cash and products. We have provided Safety Syringes, Vacutainer tubes, E-Z Care and Scrub products and the BD Insyte Autoguard with blood control to train -- and also to train and equip health care workers. With the recent launch of the Total Nucleic Acid kits on the BD MAX, the Diagnostics team has been working closely with multiple organizations to develop fully automated diagnostic tests for Ebola detection. Our molecular scientists and global partners are actively pursuing a fast, accurate and fully automated molecular detection solution that would fit in with the needs of the developing world, which is most impacted by the disease. We will continue to use our clinical knowledge and expertise to assist in this outbreak and fulfill our mission and purpose of helping all people live healthy lives. On Slide 22, before we open the call to questions, I'd like to reiterate the key messages from our presentation today. First, we are pleased with our strong fiscal year 2014 results. We have exceeded our financial and operating goals for this year, which delivered strong financial results and continued operating efficiencies. Second, our core remains strong. Our investments drove robust revenue growth of 5.2%, and we continue to deliver high-quality double-digit earnings growth of 11.4% this fiscal year. We expect to deliver a similar growth profile in fiscal year 2015 with top line growth of 4.5% to 5% and earnings growth of 8% to 9%. We're pleased with the financial performance we continue to deliver and believe we have built a strong foundation for future growth. Third, we continue to evolve and remain dedicated to becoming a customer-focused provider of health care solutions. We are excited about the acquisition of CareFusion and look forward to updating you as we continue to make progress. The powerful combination of these 2 companies will significantly accelerate our strategy. Finally, we continue to deliver superior health care products to our customers and value to our shareholders. We look forward to 2015 with enthusiasm and confidence. Thank you. We will now open the call to questions.

[Operator Instructions] Our first question is coming from Mike Weinstein of JPMorgan. Michael N. Weinstein - JP Morgan Chase & Co, Research Division: So I want to start with the guidance. It looks like the -- if I look at your FY '15 guidance versus consensus, the underlying picture's the same, but the principal difference is the impact from FX looks like it's a little bit more than The Street was modeling. And obviously, The Street was still assuming a share count. So when we think about the base off of which we add in CareFusion, any additional comments you want to make? I mean, you said at the time of the CareFusion acquisition, double-digit EPS accretion in year 1. Anything else we should be thinking about just to get our models more in line with your comments today?

So Mike, it's Vince. It was really difficult to understand what you were saying. What I picked up was that the guidance for 2015 was broadly in line on an FX-neutral basis. And so underlying, it was pretty much, I think, what you would have expected, most people would have expected, but also some people did not have the share -- cessation of the share repurchase in their estimates. So that was the first point. The second point was you were asking us, was there any update to the acquisition guidance that we're giving at all? There really isn't, but I'll ask Chris if there's anything else he'd like to say on that.

I'd like to say a couple of things, Mike. You're absolutely right that there was a mixed bag out there, a lot of moving parts, apples and oranges in terms of looking forward on '15, not the least of which is moving to a cash EPS. So I think this chart that we -- we've put up, Slide 15, was an attempt to kind of walk through that so we're all on the same page. So we got you the cash EPS. What we wanted to show is the underlying performance is very strong and consistent with what we've done over the last few years, and what we have as a goal is the 9% to 10%. We do get an impact of the fact that we're suspending the share buybacks in anticipation of the CareFusion deal of about 1%, and then the other is the headwinds from foreign currency. And we went into some detail to kind of give you not only the sense for the year, but how much of that impact is in the first quarter. So hopefully, that gets everybody on the same page. In terms of going forward on CareFusion, we'll provide much more clarity on that as we approach the deal and the deal close. And really nothing to update from what we talked about upon the announcement of the deal of the significant low-teens kind of accretion and the performance from an ROIC standpoint, et cetera. So really just a reiteration of that. Nothing new to report. We'll certainly keep everyone up-to-date as the deal progresses. Michael N. Weinstein - JP Morgan Chase & Co, Research Division: Okay. If I can follow up with one other question. And hopefully, the connection's fine here. We've had companies report different data points on the emerging markets this quarter. Your performance was strong, but we've had companies talk about Brazil not really growing this quarter. And that's as much outside of health care as in. And then there's been a number of reports about China slowing outside of health care. Are you seeing either of those end markets slow in your business? Any reason for concern that you're seeing?

So Mike, this is Vince. No, we haven't seen emerging markets slowing down, and that's across-the-board in our product categories. So it appears to us that even though there's some macroeconomic factors out there in those marketplaces, for our categories and kind of fundamentals, the governments are still investing in health care, and we saw a strong performance across-the-board, not just in China, but in all geographies. But thanks for those questions.

Your next question comes from the line of David Roman of Goldman Sachs.

I want to start with one question, Vince, to follow-up on your pipeline discussion at the end of the call, and most specifically on the BD Rx side of the business. I think you did give us a number of updates about key new products coming in the 2016 time frame. But maybe you can just sort of help give us a broader update on that franchise, how things are going with respect to gaining traction with group purchasing organizations and where you are sort of in developing an appropriate-sized product bag to make yourselves more competitive with the bigger players.

Sure. So as I mentioned in my remarks, it has been going slower, number one, and we have started to get some traction in the last quarter. But it's really fundamental to us to reorient that product line towards products that are really -- it's where safety errors, drug errors are much more important from a safety aspect. And I mentioned that we'll have 2 drugs coming out in 2016, which have those characteristics. So we're on a ramp that is slower than we thought. So we don't believe we're going to hit those initial targets in the time frame that we were talking about a couple of years ago. But we remain committed to the business. Anything else you would want to say from a portfolio standpoint, Tom?

David, this is Tom. I think, Vince, the only thing I can add is that -- to your question, David, we actually have put BD Rx successfully to a number of the large GPO agreements, so we do have that in place. We have 4 drugs launched today. As you think about -- really one of those fits that high-risk, high-value molecule, that's morphine. And as Vince mentioned earlier, the next 2 that fit that high need in a prefilled format are launching in 2016. So we'll continue to keep you updated as those progress.

Okay. Can I ask a financial follow-up question?

Sure.

Okay. So maybe just looking at the guidance just on cash flow for fiscal 2015, and maybe, Chris, you could sort of comment on what looked to be a very significant step-up in CapEx in the fourth quarter. It looks like almost it's a doubling of where the run rate has been on a quarterly basis. And then what sort of drives the -- what's driving the CapEx side and what's driving the $100 million increase in free cash flow guidance for fiscal '15?

Sure. So the CapEx situation, as we had talked about a few times last year, we're looking at spending more capital internationally, and some of that is going into our plants within China, for example. And so a lot of that hits -- it's a lumpy kind of thing, and we knew it would be and we kind of expected it to hit in the fourth quarter. So we weren't surprised by that. And so we came in about where we expected to for the year. We have ramped that up again next year and pretty much for the same reason, a little bit more in the way of international spending, which we think is prudent and certainly is resulting in good returns. In terms of operating cash flow, really it's the total income flowing down through the operating cash flow. Sometimes that gets a little lumpy, as you know, in terms of timing of payments, et cetera, and the working capital. But as we look out next year, we see most of that flowing through, and everything else kind of staying neutral. So you get the benefit of that going up in the total cash flow.

Your next question comes from Rick Wise of Stifel. Frederick A. Wise - Stifel, Nicolaus & Company, Incorporated, Research Division: A couple of questions. First, U.S. Medical, can you give us a little more color? U.S. Medical seemed a bit soft. I mean, I guess that's U.S. Safety. Any more color on what's happening there? I mean, it sounds like you see the environment as stable. Just remind us again what's happening there -- happened there in the fourth quarter and what may or may not change in the year ahead.

Sure. Tom Polen will do that for you, Rick.

Rick, this is Tom. So as you said, as we've mentioned before, the U.S. market we do view as mature from a Safety perspective, but we also view it as stable. One of the things to note is that, in addition, the U.S. Safety sales in the quarter did reflect a small regional reclassification of certain sales related to the Safety Syringe acquisition. And so with that reclass, actually growth was slightly positive for the quarter in the Medical segment. And due to this change, our U.S. Safety growth rate may be just a little bit lighter for the next couple of quarters, with a corresponding uptick in international as that reclassification annualizes. Frederick A. Wise - Stifel, Nicolaus & Company, Incorporated, Research Division: Got you. And Vince, some of your recent public comments on G&A, you basically said, I think publicly, that x the China investment and EVEREST, that G&A is coming down and you're starting to see it come down. You used language like that, if I'm quoting you accurately. Just remind us, where are you with those investments. And just specifically on China, do you have to keep spending the $40 million per year to drive the growth we're seeing? Does that come to an end at some point? Just any more color there would be helpful.

Sure. So Rick, that's 2 pieces. One is overall G&A has been coming down as a percent of sales as we move processes into shared service centers around the globe, and we believe we have much more to do in that area, number one. Number two, as we look at synergies with CareFusion, we'll be taking an all-in company look at that from an end-to-end business process standpoint. So more work to be done there and more opportunity. Now in terms of investments in emerging markets, it's more the investment in the sales and marketing side. There is some investment in G&A, but less going into G&A, more going into coverage build as we build into Tier 2 in China, and we continue to expand coverage in other geographies. In this plan, Rick, for 2015, we continue to have a significant investment in emerging markets to drive top line growth. So it's not so much G&A as it is the sales and marketing side.

Your next question is coming from David Lewis of Morgan Stanley.

This is actually Scott Lange in for David Lewis. Just 2 quick ones for me. First, Vince or Bill, you've now had the chance to spend some more time with CareFusion management and delve a little deeper into the integration planning. Can you share your updated thoughts around the fit of Infection Prevention? And also the ventilation business and whether that's a priority, longer term, for the pro forma company?

So I'll take that one. We're still very early on in terms of looking at the portfolio. What I've said is that we will go through the same kind of strategic review we go through all of our product lines, number one. Number two, we'd be looking to see if we can develop leading positions with those product lines. And then based on that, we'll decide exactly where we're going to invest our money. And that work will go on over the next few months and will crystallize where we're going to come out, but it would be premature to say anything past that. We have seen some very exciting opportunities in those businesses. So we'll get back to you later as we clarify both strategically and financially on the deal.

Fair enough. Can you also comment a little bit on share dynamics within Diagnostics, in particular in the molecular space? And also, give us some color as to why restructure the operations now versus later on down the line?

So I'll take the second half of the question, and then I'll ask Linda and Alberto to comment specifically about Diagnostics and Life Sciences. So the work that we started was about a year ago to look at more solutions for the customer, and we started around individual businesses. You saw that in microbiology with the acquisition of KIESTRA, and you've seen how successful we have been with that plug-in acquisition. Linda's role on the Life Science side started with 2 of the 3 businesses, and the idea was to begin the work on what strategies can we develop more broadly around solutions, leveraging across the segment. We have not restructured the segment nor restructured those businesses. But this is more of a strategic thrust, looking at how we work across businesses and strategies that cross -- that can cross those businesses. And Linda started that work a year ago, and we will accelerate that work. Some of that work resulted in the acquisition of GenCell. So that's that piece. If we come to what's happening in Molecular, Linda, I'll ask you to make a first comment, and maybe Alberto will fill in some details.

Sure. So thanks, Linda here. So first on the Molecular side, just broadly. As we've reported, we continue to see some share loss relative to our ProbeTec business; and also in our Women's Health and Cancer, also affected by the interval testing. We also, though, on a share gain, are doing very well with our core micro business, with our flu business and also increased placements on our MAX systems. Alberto, I don't know if you want to add anything to that.

No, I think that's where -- we're seeing most of the share loss in the ProbeTec business, as you mentioned. On some older platforms, we're seeing some much more modest share erosion in some of the MRSA. But with the new assay in MRSA XT, we think that we can actually regain the momentum backwards. And also with our enteric launches and -- we think that we can build that momentum. But we're growing the other categories in MAX. So we're actually very happy with the momentum that we're actually getting with the platform.

Alberto, you might want to comment on where we stand with that one big account that we lost, which has been the majority of the share loss.

That's on the CT/GC side, and it's -- we expect a little bit more of -- it's mostly behind us, is the good news.

Yes.

So that's going to be annualized into -- going into next year. There's still a little bit still left in the first quarter, but to a much lesser extent this year. And after that, we're basically done and annualized.

So year-on-year, we're starting to see the growth rate in that business go up when you net all that together, right?

Correct.

Your next question is coming from Kristen Stewart of Deutsche Bank.

I just want to go back, Chris, on the comments you'd made on the operating margin side. Can you maybe just go back and parse out how much of the operating margin movement is related to FX and pension? And then, what the kind of core expansion is for '15 relative to what you saw in '14?

Sure. So let's start, Kristen, with '14. '14 was basically about 70 basis points of underlying margin expansion, which was in line with what our expectations were. But as we had said throughout last year, we actually had a pension tailwind last year based on where the interest rates were as of the beginning of last year. So that accounted for about half of that. And then on a -- on a kind of a reported basis, including FX, you had about 70 basis points of FX pressure. And then just to complete the dots there, you also had additional 20 of the medical device tax, which flowed into the first quarter. So essentially the way to think about that is 70 basis points underlying and offset essentially by FX, and then a little bit of pressure down of 20 basis points for Medical device. As we look at '15, we're looking at the underlying margin expansion being 40 to 50 basis points. But as you probably know, pension flips the other way and the interest rates go the other way. And about half of that 40 to 50 will be pension headwinds going forward. We get a little bit of pressure from FX and not quite as much on the margin basis, as you saw this year. So probably 20 basis points or thereabouts of pressure from FX in the operating margin going forward.

Okay. So the pension amount is not included within the 40 to 50. So it's 40 to 50 underlying.

That's right.

And then pension takes that down about half?

About half, exactly. So kind of a flip to the story in '14.

Okay. Perfect. And then just in terms of CareFusion, I know there's been a lot of discussion out there on their aspirations for operating margin improvement. So I think they've quantified about 100 basis points here. Can you maybe just help us understand what you've said related to the acquisition with the incremental cost synergies and some of the margin expansion that you may be looking towards that may perhaps double count if -- some people are looking at their targets?

Sure. Yes, thanks. So what we had said when we made the announcement is that there would be $250 million of synergies, as you know. Now when we were looking at the pricing and what we would be interested in paying for CareFusion, we did our own modeling. We actually did baseline that at around 70 basis points of margin improvement, which is, quite frankly, still pretty high-stepping to get to 70 basis points, and a lot has to happen. So that's the way we valued it, and the $250 million was incremental to that. If you were modeling 100 basis points a year for the next 3 years, you should think maybe $200 million on top of the 100 basis points. So there is about a $50 million overlap on some of the things that we think are more likely to be done as we -- through synergies than would have been able to be done on a standalone basis.

Your next question comes from Bill Quirk of Piper Jaffray.

First question, just hoping some additional details on the Diabetes franchise. I'm just trying to get a little better handle on the background from the underlying growth, and just talk to us a little bit about the sustainability here.

Sure. Tom Polen can take that. You saw it was another strong quarter for Diabetes Care. Tom?

Bill, this is Tom. As you mentioned, overall a strong year for diabetes, driven, as Vince mentioned before, by new product launches, specifically the Nano Pen Needle, which continues to have very strong adoption around the world. I think in regards to your question around underlying growth, obviously in Q4, we did have a very strong quarter at 8.1%. Q4 was favorably impacted by a prior year comparison, and we do believe that, that growth rate is a little bit above the underlying growth of the business. And so we think back in perspective of the Medical segment growth in '15 guidance being in that 4.5% to 5%, we certainly see Diabetes Care on the upper side of that as one of the higher-growth businesses within the segment. And we see that sustaining going forward, which is maybe not at that rate that you're seeing in Q4 due to some onetime activity there.

Okay. Got it. And then just thinking about the flu season. Obviously, the Southern Hemisphere has been going through or went through a pretty severe one. There's some expectations here that we're going to see that ramp up this year as well. Certainly, we've seen some companies suggest that we've seen a little bit of stocking of product ahead of kind of the traditional season. So I'd be just curious what you guys are thinking about the flu season here for this coming year or kind of what's dialed into guidance, et cetera.

Alberto will take that one for you.

So our assumption is based on a normal flu season, that's what's incorporated into our numbers. Having said that, we are seeing some early stocking. You're right. But right now, we're not taking -- we're not assuming the assumption that this will -- that this eventually will filter through the system. And we're still assuming that, overall, it's going to be a normal flu season. If it's above that, obviously we'll communicate that at that point.

Your next question is coming from Doug Schenkel of Cowen and Company.

Your initial growth guidance range for the year is a little bit more narrow than we've seen from you guys. Last couple of years, you've guided to a broader range. This year, it's a little bit tighter. Just wondering if that is indicative of more confidence in the outlook, better visibility heading into fiscal '15 or something along those lines.

So I would say probably better visibility, and we've had a couple of years of a more stable environment. So that kind of gave us the confidence to narrow the range, nothing more than that at this point in time.

We narrowed the range last year fairly quickly. I think right at the end of the first quarter, we narrowed it pretty closely. So not that different.

Okay. And years ago, when we saw big changes in oil prices, we used to talk about related fluctuations in resin prices and how that might impact your margin outlook. Over the years, you've clearly made pretty significant efforts to mitigate this impact. I just wanted to make sure that there isn't any potential for margin benefit associated with this dynamic heading into fiscal '15.

So there's 2 different things going on. One is the price of oil is coming down, and of course, we would see that as a good thing. But there is not the capacity in the resin market to let all of that flow through. In fact, there was a problem at one of the plants. There was a fire at one of the suppliers. So capacity is tight. So we are not forecasting that flowing through for the time being. That could change over time. But right now, we don't have any visibility to that.

And you do get a little bit of a lift in terms of shipping prices, or whatever, from vendors as oil prices go down, and that's already baked in.

Your next question comes from Brandon Couillard with Jefferies.

Vince or Chris, in terms of the debt related to the CareFusion deal, are you able to lock that in, those debt terms in earlier rather than later at all? And when would you expect to complete or start the financing or the funding for that?

Yes, the answer is you can. As you know, the interest rates ticked down a bit fortuitously, and so we were able to take the opportunity to lock in some of that appropriately. And so we did take the opportunity to do that. We're in the process of rolling that out right now in terms of when we would actually do the financing. As we get greater visibility to different things like HSR, that type of thing, we'll have more confidence. But clearly, you want to do that in advance of the closing as you're gaining confidence in terms of the -- when the timing, more than anything else, of the close from an HSR standpoint. So you would see us do that in advance, particularly to take advantage of the rate environment.

And secondly, in terms of the restructuring or workforce reduction, what should we anticipate for the payback for that action to be in '15?

It's in the guidance, and so some of that does flow through. Maybe a 1/4 of that amount would flow through because of the amount, the severance payment and the like.

Your next question comes from Brian Weinstein of William Blair. Brian Weinstein - William Blair & Company L.L.C., Research Division: A question on the infusion set launch. It looks like it's a little bit ahead of where the guidance was for the launch. Can you talk about what changed there? And also can you comment a little bit on the market opportunity and how fast you expect to penetrate this?

So it's very close to what we were thinking, Brian. So nothing significant changed. We're making good progress on getting the manufacturing equipment installed and whatnot, that's probably the biggest thing. But Tom, anything else that you would say on that?

No, I think we'll obviously continue to update, post approval, more information on our launch timing. We're certainly, Brian, we're very excited about the -- this is a logical adjacency to our core diabetes pen and syringe business and add another growth driver to that organization. And we do see the opportunity to take that product both direct and through partnerships, and I think that's all we'd comment on at this point in time. Brian Weinstein - William Blair & Company L.L.C., Research Division: Okay. And then, Chris, can you comment a little bit about FX exposure by currency and kind of update us on that? And then typically we had thought about 30% to 40% of your top line exposure kind of falling through to the bottom line, given the fact that you're not doing any hedging. Has that changed at all?

Sure. So the impact that you will see -- because clearly everyone knows that the euro is down comparatively with all of last year, all of '14 for the most part. In fact, we pegged this at $1.27, it's down even a tick from that. And -- but then you also see weakness in the Japanese yen year-over-year. The Brazilian real is weak. The Canadian dollar is weaker. So all of those things, as I said my prepared remarks, they were significantly down, particularly in the first quarter. And so that's why the impact in the first quarter is greater on the bottom line than the 400 basis points we said for the year. It's really impacting the first quarter. In terms of the other way to think about it, it's difficult to give any kind of direction on that because, as you know, we have the profit and inventory impact, and we've talked a lot about that. If you remember in the first quarter of last year, it was kind of hitting us. And so it's hard to give any particular guidance around how much drops to the bottom. It depends on an awful lot of different factors. So it's hard to model, is probably what I'm saying, because of the profit and the inventory piece.

Your next question comes from Vijay Kumar of ISI Group.

I think most of my questions have been asked. I had a couple of follow-ups. One I guess, Chris, you were mentioning on the deal closure timing. So apart from HSR, is there -- are there any other regulatory approvals that we need to be aware of, which could cause some uncertainty around the closure timing?

Well, it is the HSR and Europe, the equivalent in Europe would be the other. So those would be the most variable. And then obviously, you have the SEC review. We'll be filing the S-4 shortly, very shortly, and then that kind of starts the clock on their review. And which the hope is that the 2 of them come together nicely, but it is very variable. So we'll update you more on that as things progress.

And then one follow-up on the guidance front. When you look at your Life Science segment, really I thought the growth assumptions out there were better than expectation. I mean, particularly on Bioscience. Is this all new product driven? Or can you talk about sort of what's really driving growth in the Biosciences?

So in Biosciences, you saw some really nice bounce back last year in the high-end instrumentation and some good performance with the Sirigen dyes as well. So you have that as the fundamental. And I think, Linda, we're forecasting that to continue to improve, and you have some new products that you're launching.

Yes. So thanks, Vince. So across the board in our Life Sciences business, first of all, you saw we see increased stability in both U.S. and Europe in terms of the funding environment, and then very strong performance in our emerging markets business. So as Vince commented on, our Life Science research reagents, very strong performance, upside in clinical or instrument base and also our AB business. So across the board, seeing some nice growth. We expect, again, 4.5% to 5% heading into next year, which is pretty much what we saw this year.

Your next question comes from Glenn Novarro of RBC Capital.

I had 2 questions on the gross margin. If you look at fiscal 4Q, it came in 70 basis points below our forecast. Now I'm just wondering, did the gross margin come in below your forecast as well? And I know pricing wasn't a big hit, and I was wondering if you can give us any put and takes and any additional color. And then as my follow-up, I think you may have -- hopefully, I wrote this down correctly, you're guiding to a 52% gross margin for fiscal '15, which is an improvement over fiscal -- just over fiscal 4Q. And if I wrote this down correctly, what are some of the improvements and drivers of the better gross margin for next year?

Okay. So let me take a shot at that. For the fourth quarter, it came in pretty much upon our expectations. So we had been talking about the drag from pricing in the fourth quarter all year long. So that hit about where we expected. The only thing that I would say, it was probably about a 10 basis points more FX drag than we had anticipated, so that was the biggest difference from what our expectations are. And then I'm trying to think of what your other question was. Oh, the -- in terms of going forward, margin guidance, take a look at the chart that we took you through on Chart 16, because we reset on an adjusted cash EPS basis. And so the full year gross profit margin for fiscal 2014 was 51.2%, but then adjusted on a cash EPS basis kind of new foundation, that's 52%, and our guidance was about 52% as well. Now we actually get a little bit of a lift from operational improvements, the traditional things, ReLoCo and continuous improvement. But we also said that we have some unfavorable pricing in '15 and some pension headwinds as well, and the combination of those things get you at about 52%. So hopefully that gets you there.

Your next question comes from Richard Newitter with Leerink Partners.

This is Ravi in for Rich. Just a question on the Ebola and potential government spending. Is there any of that built into the Biosciences guidance? Or are you considering any potential spending allocation increases there in that segment?

No, we have not built that in -- we don't have any direct visibility to any program that we could put in at this point in time. As we said, we are doing some work with partners on some diagnostic test development, but we don't think it's a big opportunity at this point.

Great. And then sort of maybe the last one is a little bit more on GenCell, trying to understand the company's longer-term aspirations in Next-Gen Sequencing.

Sure. Linda can talk to that.

So thanks. Very excited about the acquisition of GenCell. Really if you think about the company, GenCell and then the NGS space, we really see a big movement now occurring from the research to the clinical space. And as we looked at overall NGS and an upfront sample and library prep, the fact that this takes upwards of 2 days to occur today is just too long if we bring it to the clinic. So GenCell really provided us the opportunity to get into that library prep space and really consolidate the workflow, automation, scalable throughput. So a lot of advantages we see here. And then as you think longer term about BD's position in the space, thinking about the work we do today with QIAGEN on our sample collection side and being able to expand upon that right through to the work we do in Diagnostics. As this moves to infectious disease, we see a lot of opportunities to provide BD skills combined with the technology of GenCell over the long term.

So this is a very targeted play that Linda was talking about. We're not talking about going into sequencing. This is really leveraging, as Linda was mentioning, capability we have that comes out in Molecular Diagnostics and sample processing, PAS, also in sample collection and sample processing that we have had a joint venture, that's what Linda was mentioning. For a number of years now, that has been growing quite nicely. So it's a sample processing, laboratory prep, automation, leveraging the skills we have down at DS. So it's all of that together, but in a very targeted way.

Your next question comes from Derik De Bruin of Bank of America Merrill Lynch.

A lot of my questions have been answered, but I just want to clarify something. On your guidance for '15, does this include anticipated financing for the CareFusion acquisition in your interest expense? I guess, can you give us some clarity on sort of like your net interest income or interest expense guide?

Sure. No, it doesn't anticipate any additional financing for CareFusion. We wouldn't know the timing, et cetera. So it's not in there.

Okay. And the -- even on an adjusted fiscal '14 basis, your -- even in '15, your tax rate's down pretty significantly next year. How sustainable is that? And can you remind us on the combined tax rate that you're looking at for BD and CareFusion?

Sure. So as you've seen over the last 3 or 4 years, we've made very good progress on the effective tax rate, bringing it down from somewhere north of 28% to this current range. You saw a good performance. We've done a lot in terms of building out legal entities internationally and putting structures in place. So you continue to see the benefit of that flowing through the rate as well. And as we think about the combination with CareFusion, I think as I mentioned when we had that call, that we just took their tax rate and our rate combined. We didn't evaluate it or we didn't include any synergies. What we did include is the tax yields from the financing, the debt that we had. So that was in the neighborhood of 50 to 100 basis points. Hard to calculate because there's a lot of moving parts, so we gave you the number. But longer term, we do see an opportunity to get some synergies and to put some of their revenues into our structure. And as we drive their revenues internationally, you'll see some benefit of that as well. But that's more blocking and tackling that needs to occur over the first couple of years and will bear fruit going forward. So continued sustainability of the ability to get the rate down. I think I've talked about the fact that when we look at our peer group, they tend to be still better than where we are. We're getting closer, but that's stuff that is basic blocking and tackling that we've been putting in place for years, and we're now seeing the fruit of that each and every year. One thing that I would mention about next year is that we do have the potential for the R&D tax credit to be reenacted. And so the way to think about that is if it does happen, the low end of our range would be more likely. And if it doesn't, we'll be above that, but it does contemplate the potential for that to occur as well. I guess my answer was too long.

Your next question comes from Mark Massaro of Canaccord Genuity.

Maybe a question for Alberto. Could you please update us on the installed base of the BD Veritor, maybe discuss the competitive environment dynamics? And are you guys planning any additional investments in the technology, I'm thinking maybe cloud-based solutions or the like?

Yes. So our -- we estimate our installed base at the end of the quarter to be around 14,000 units. So that's where we are on that. And yes, we are working on our next-generation Veritor that will have connectivity associated with it. So yes, we are working on that, in addition to other assays as well.

Yes. Okay. Thanks very much, Mark.

And maybe just a quick follow-up. What is the timing of CT/GC on BD MAX?

So as mentioned the -- in Europe, we're -- it's filed, so we're waiting for the approval that we're estimating around Q3. That's when we estimate the approval in Europe.

Right. And then for the U.S.?

For the U.S., we're working on a next-generation assay that will be more into '16, and we'll update when we have a little bit more visibility on the date.

With that, I will turn the floor back over to Vince Forlenza for closing remarks.

Okay. So thank you very much for your participation today. It was a pleasure to update you on a strong performance in 2014 and some strong guidance for 2015. We will be updating you on progress with the CareFusion acquisition as that gets closer, and we look forward to doing that and talking to you soon. Thank you very much.

Thanks, everyone.

Thank you.

Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.